Valuation
PharmaceuticalsLive · Yahoo FinancePrice
$350.53
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
SWOT Analysis — AMGN
Inflationary BoomStrengths
Net Income: $7.7B (+88.5% YoY) — Profit grew 89% — the company kept more of each dollar earned.
EPS (Diluted): $14.23 (+88.2% YoY) — Earnings per share rose 88% — each share earned more.
Revenue: $25.4B (+8.8% YoY) — Revenue grew 9% — the company sold more goods or services than the prior year.
Weaknesses
Operating Cash Flow: $10.0B (-13.3% YoY) — Operating cash flow fell 13% but remained positive.
Opportunities
Gross Profit: $4.7B (+2.4% YoY) — Gross profit rose 2% — the spread between revenue and direct costs improved.
Threats
Current ratio of 1.14x — thin liquidity buffer against short-term obligations.
Financial Charts
Revenue vs Net Income
Gross Profit vs Operating Income
Margin Trend
Operating Cash Flow
Year-over-Year Changes
Net Income
$7.7B
was $4.1B
Profit grew 89% — the company kept more of each dollar earned.
EPS (Diluted)
$14.23
was $7.56
Earnings per share rose 88% — each share earned more.
Operating Cash Flow
$10.0B
was $11.5B
Operating cash flow fell 13% but remained positive.
Revenue
$25.4B
was $23.4B
Revenue grew 9% — the company sold more goods or services than the prior year.
Gross Profit
$4.7B
was $4.6B
Gross profit rose 2% — the spread between revenue and direct costs improved.
Risk Flags
0 high · 1 medium · 0 low- ◈ Medium
Current ratio of 1.14x — thin liquidity buffer against short-term obligations.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubFiling History — AMGN
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade AMGN
Links open broker research pages. Not an endorsement or recommendation.
Research Amgen Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.